Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy
Outcomes for resectable SNMM patients continue to be poor in the immunotherapy era. In the context of selection bias, neoadjuvant Ipi/Nivo was not associated with better outcomes in all-comers. However, those with evidence of response to Ipi/Nivo had better prognosis.
Authors
- Andrew Justin Bishop (ORCID: https://orcid.org/0000-0002-7737-8023)
- Shirley Y. Su (ORCID: https://orcid.org/0000-0002-3903-8204)
- Devarati Mitra (ORCID: https://orcid.org/0000-0002-2225-164X)
- Rodabe Navroze Amaria (ORCID: https://orcid.org/0000-0001-6876-278X)
- Ahsan Saleem Farooqi (ORCID: https://orcid.org/0000-0001-9605-7113)
- Melissa Chen (ORCID: https://orcid.org/0000-0002-3274-2653)
- B. Ashleigh Guadagnolo (ORCID: https://orcid.org/0000-0002-4489-7070)
- David Swanson (ORCID: https://orcid.org/0000-0003-3174-1656)
- Michelle D. Williams (ORCID: https://orcid.org/0000-0002-9133-7332)
- Ehab Y. Hanna (ORCID: https://orcid.org/0000-0003-3241-2440)
- Jennifer L. McQuade (ORCID: https://orcid.org/0000-0002-2393-2172)
- Aya F Salem (ORCID: https://orcid.org/0009-0005-8216-5005)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1002/hed.28098
- Citations
- 7
- Primary Topic
- Ear and Head Tumors
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- Radiological Society of North America
- National Cancer Institute
- National Center for Advancing Translational Sciences